Cancer immunotherapy using sindbis virus replicon particles encoding a VP22-antigen fusion

Human Gene Therapy

Volumn 13, Issue 4, 2002, Pages 553-568

  Cheng, Wen Fang ^a,b   Hung, Chien Fu ^a   Hsu, Keng Fu ^a,c   Chai, Chee Yin ^a,d   He, Liangmei ^a   Polo, John M ^e   Slater, Leigh A ^a   Ling, Morris ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; NAKED DNA; RNA; TUMOR ANTIGEN; VIRUS VECTOR;

ALPHA VIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL LINE; CONTROLLED STUDY; DNA REPLICATION; GENE TARGETING; HERPES SIMPLEX VIRUS 1; IMMUNIZATION; MOUSE STRAIN; NONHUMAN; PACKAGING; REPLICON; RNA REPLICATION; SINDBIS VIRUS; STEM CELL; T LYMPHOCYTE; VACCINATION; VIRAL CONTAMINATION; VIRUS RECOMBINANT; VIRUS REPLICATION; WART VIRUS;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE TRANSFER TECHNIQUES; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; REPLICON; SINDBIS VIRUS; VACCINES, DNA; VIRAL PROTEINS;

ALPHAVIRUS; ANIMALIA; HUMAN HERPESVIRUS 1; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; SIMPLEXVIRUS; SINDBIS VIRUS;

EID: 0036204348     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252809847     Document Type: Article

References (34)

1. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
2. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
3. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
4. Sindbis virus expression vectors: Packaging of RNA replicons by using defective helper RNAs
5. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen
6. Enhancement of Sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments
7. Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7
8. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule
9. Alphavirus-based vectors for vaccine and gene therapy applications
10. Intercellular trafficking and protein delivery by a herpesvirus structural protein
11. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
12. Alphavirus-based expression vectors: Strategies and applications
13. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein
14. Recent advances in gene expression using alphavirus vectors
15. DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector
16. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
17. Sindbis virus vectors for expression in animal cells
18. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen
19. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein
20. The NK-1.1(-) mouse: A model to study differentiation of murine NK cells
21. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
22. Preventive and therapeutic vaccines for HPV-associated cervical cancers
23. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis
24. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity
25. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors
26. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement
27. Alphavirus vectors for gene expression and vaccines
28. Heat shock proteins transfer peptides during antigen processing and CTL priming
29. The alphaviruses: Gene expression, replication, and evolution
30. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes
31. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
32. Engineering an intra-cellular pathway for MHC class II presentation of HPV-16 E7
33. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells
34. Cancer therapy using a self-replicating RNA vaccine